Site search
2831 results for '' found
BTM utilisation for burn scar contracture - long term outcomes (Trial Not Registered)
BTM utilisation for burn scar contracture - long term outcomes (Trial Not Registered)
/
Breathing Control Training (BCT) as a Treatment for Functional Seizures (FS) – a multi-centre, assessor-blinded, randomised controlled efficacy and acceptability trial (ACTRN12622000525785)
Breathing Control Training (BCT) as a Treatment for Functional Seizures (FS) – a multi-centre, assessor-blinded, randomised controlled efficacy and acceptability trial (ACTRN12622000525785)
/
An Open-label, Multicenter, Randomized Phase 3 Study of First-line Encorafenib Plus Cetuximab With or Without Chemotherapy Versus Standard of Care Therapy with A Safety Lead-in of Encorafenib And
An Open-label, Multicenter, Randomized Phase 3 Study of First-line Encorafenib Plus Cetuximab With or Without Chemotherapy Versus Standard of Care Therapy with A Safety Lead-in of Encorafenib And
/
A Phase Ib/IIa, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose, Parallel-Group Study To Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ro71
A Phase Ib/IIa, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose, Parallel-Group Study To Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ro71
/
A PHASE I, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF RO7589831 AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN
A PHASE I, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF RO7589831 AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN
/
An open-label, phase 1 / 2 study to evaluate the safety, pharmacokinetics and preliminary anti-tumour activity of Englumafusp Alfa [RO7227166, A CD19 targeted 4-1BB ligand] in combination with Ob
An open-label, phase 1 / 2 study to evaluate the safety, pharmacokinetics and preliminary anti-tumour activity of Englumafusp Alfa [RO7227166, A CD19 targeted 4-1BB ligand] in combination with Ob
/
Bringing Optimised COVID-19 vaccine Schedules To Immunocompromised populations (BOOST IC) an adaptive randomised controlled clinical trial (NCT05556720)
Bringing Optimised COVID-19 vaccine Schedules To Immunocompromised populations (BOOST IC) an adaptive randomised controlled clinical trial (NCT05556720)
/
Bone Loss Prevention with Zoledronic Acid or Denosumab in Critically Ill Women – A Randomised Controlled Trial (NCT04608630)
Bone Loss Prevention with Zoledronic Acid or Denosumab in Critically Ill Women – A Randomised Controlled Trial (NCT04608630)
/
Brain Oxygen Neuromonitoring in Australia and New Zealand Assessment - Global Trial (BONANZA-GT) (ACTRN12619001328167)
Brain Oxygen Neuromonitoring in Australia and New Zealand Assessment - Global Trial (BONANZA-GT) (ACTRN12619001328167)
/
A phase Ib open-label, multicenter study evaluating the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with pirtobrutinib in patients with relapsed or refractory chronic l
A phase Ib open-label, multicenter study evaluating the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with pirtobrutinib in patients with relapsed or refractory chronic l
/